Publications

Read Now

April 1998
Case

Cephalon, Inc.

By: Peter Tufano

In early 1997, Cephalon, awaited an FDA panel's decision on whether its drug, Myotrophin, would be approved. If the drug was approved, the firm might need substantial additional funds to commercialize as well as to buy back rights to it (which had been sold earlier to... View Details

Keywords: Risk Management; Financing and Loans; Health Care and Treatment; Pharmaceutical Industry; United States

11 Jun 2014
Research & Ideas

In the Future of Sports Investing, Media Is the Best Bet

redefined," Higgins says. "The younger generation doesn't care as much about cable TV." And for older sports fans, mobile devices are gaining popularity because they allow for multitasking. "Wyc Grousbeck was on a tour... View Details

Keywords: by Carmen Nobel; Sports; Financial Services

February 2022
Case

Leading The UK Vaccine Task Force

By: Amy C. Edmondson and Claudia Pienica

This case describes the first six months of the UK Vaccine Taskforce, under the leadership of Kate Bingham. With a career spent in the private sector as a biotech investor, Bingham’s appointment within the government was considered unusual. The overarching brief given... View Details

18 Dec 2012
First Look

First Look: December 18

Care (forthcoming) Abstract Background: Teamwork in health care settings is widely recognized as an important factor in providing high quality... View Details

Keywords: Carmen Nobel

August 2013 (Revised October 2013)
Case

MedImmune Ventures

By: Richard G. Hamermesh and David Lane

Ron Laufer is the new Senior Managing Director of MedImmune Ventures, the corporate venture capital arm of AstraZeneca, a leading pharmaceuticals firm. Laufer has to decide whether to pursue a high-potential, but very risky, early-stage investment. The decision Laufer... View Details

Keywords: MedImmune; MedImmune Ventures; AstraZeneca; NeuProtect; Corporate Venturing; Biotechnology; Venture Investing; Venture Capital; Health Care and Treatment; Pharmaceutical Industry; Financial Services Industry; Biotechnology Industry; United States; Australia; Europe; London

December 2005 (Revised April 2010)
Teaching Note

Leerink Swann & Co.: Creating Competitive Advantage (TN)

By: Boris Groysberg and Andrew N. McLean

Keywords: Health Care and Treatment; Capital Markets; Banking Industry

October 2013 (Revised April 2015)
Case

Myomo: Getting Sales in Motion

By: Frank V. Cespedes, Shikhar Ghosh and Matthew Preble

In late 2012, the management team of Myomo, a startup which had designed a unique myoelectric arm brace for patients with dysfunctional arms, was deciding which of the three sales models the company had tested to pursue as its sales strategy going forward. Each model... View Details

Keywords: Technological Innovation; Information Technology; Marketing Strategy; Decision Choices and Conditions; Health Care and Treatment; Business Startups; Sales; Growth and Development Strategy; Health Industry; Health Industry

November 2016
Case

Pete & Gerry's

By: Jose Alvarez and Natalie Kindred

November 24, 2020
Article

4 Strategies to Make Telehealth Work for Elderly Patients

By: Umar Ikram, Susanna Gallani, Jose F. Figueroa and Thomas W. Feeley

As providers have ramped up their use of telehealth during the COVID-19 pandemic, one group—the elderly—has experienced particular challenges in adopting the technologies. This article describes the strategies four innovative provider organizations have used to engage... View Details

Keywords: Telehealth; Health Pandemics; Health Care and Treatment; Internet and the Web; Age; Technology Adoption; Strategy

Register to Read

December 5, 2024
Article

A Consensus Definition of Creativity in Surgery: A Delphi Study Protocol

By: Alex Thabane, Tyler McKechnie, Phillip Staibano, Vikram Arora, Goran Calic, Jason W. Busse, Sameer Parpia and Mohit Bhandari

Introduction
Clear definitions are essential in science, particularly in the study of abstract phenomena like creativity. Due to its inherent complexity and domain-specific nature, the study of creativity has been complicated, as evidenced by the various... View Details

Keywords: Creativity; Health Care and Treatment; Outcome or Result; Measurement and Metrics

Register to Read

May 2023 (Revised June 2023)
Supplement

Novartis (B): Reimagining Medicine

By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi

This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,... View Details

Keywords: Health Care and Treatment; Business Model; Production; Business Strategy; Pharmaceutical Industry

Article

Managing the Use and Dissemination of Information about Biomarkers: The Importance of Incentive Structures.

By: Ariel Dora Stern

The use of biomarkers holds great promise for the development of new therapeutics and the acceleration of clinical research. However, biomarkers must be validated—a complex and costly endeavor. Importantly, biomarker validation is meaningfully shaped by economic and... View Details

Keywords: Biomarkers; Information Management; Health Care and Treatment; Motivation and Incentives

Find at Harvard

Read Now

November 1978 (Revised October 1989)
Case

Amicon Corp. (B)

Details the negotiation between Amicon and three potential licensees, Jackson, Maynard-Smith and Behrstein. View Details

Keywords: Technology; Patents; Negotiation Process; Negotiation Participants; Health Care and Treatment; Biotechnology Industry